"Now the only option will be to find the best possible deal on traditional forms of the drugs," says NYU's Alexandra Sowa, MD ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a much-awaited entry into the world’s most populous ...

US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro (tripeptide). The launch of this breakthrough medicine is an important step toward dealing ...

Eli Lilly and Company launched its weight loss drug Mounjaro in India on Thursday after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). This is a drug which ...

Eli Lilly's MounjaroNow, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).

With diabetes and obesity cases surging in India, pharmaceutical giant Eli Lilly and Company (India) has launched Mounjaro (tirzepatide), a once-weekly injectable drug for chronic weight ...

Manchanda of Systematix said that if even 0.5% of them use Mounjaro, it would fetch sales of $1.5 billion for Eli Lilly every year, since the annual cost works out to ₹6.5 lakh per patient.

(MENAFN- Golin Mena) Bengaluru, March 20, 2025: Eli Lilly and Company (India) today announced the launch of Mounjaro® in single-dose vial presentation following the marketing authorization from ...